Health

Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024

* Laekna has developed a proprietary antibody-based drug discovery platform of activated hepatic stellate cells (aHSC) depletion for liver fibrosis. * Derived from the platform, LAE105 is a potentially first-in-class drug candidate that depletes aHSC in the fibrotic liver by harnessing innate ...

2024-01-04 12:40 1600

IASO BIO Announces New Development Partnership with Umoja Biopharma to Develop Ex Vivo and In Vivo Cell and Gene Therapies

SAN JOSE, Calif., SHANGHAI and NANJING, China, Jan. 3, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products,today announced a new set of collaborations wi...

2024-01-04 05:30 2253

GPN Vaccines Reports Positive Safety and Immunogenicity Data from its Phase 1 Trial of Gamma-PN

ADELAIDE, Australia, Jan. 3, 2024 /PRNewswire/ -- GPN Vaccines Ltd, a clinical-stage biotechnology company developing a Streptococcus pneumoniae vaccine to prevent life-threatening pneumonia, bacteraemia and meningitis, is pleased to announce positive safety and immunogenicity data from its Phase...

2024-01-04 04:30 1850

WuXi XDC Enters into Partnership Agreement with IntoCell, Enabling Clients to Accelerate ADC Discovery and Development

SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and IntoCell, a Korean biotechnology company dedicated to developing novel ADC platform technologies, ...

2024-01-03 09:28 1739

Meihua International Medical Technologies Co., Ltd. Announces Closing of Initial $6 Million Tranche of Potential $50.5 Million Maximum Offering

YANGZHOU, China, Jan. 2, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries inChina, today announced the closing of i...

2024-01-03 06:19 4447

MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation antibody drug conjugate in Oncology

SUZHOU, China, Jan. 2, 2024 /PRNewswire/ -- MediLink Therapeutics ("MediLink"), announced today that it has entered into a worldwide collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) on the development of a next-generation antibody-drug conjugate candidate YL211, targeti...

2024-01-02 22:00 1737

Innovative Smart Sports and Digital Health Tech From ITRI Debut at CES 2024

LAS VEGAS, Jan. 2, 2024 /PRNewswire/ -- The Industrial Technology Research Institute (ITRI) , Taiwan's largest and one of the world's leading high-tech applied research institutions, today announced the introduction of smart sports and digital health innovations atCES 20...

2024-01-02 22:00 2037

JJ's House Joins Forces with Sisters in the Fight Breast Cancer Foundation to Make Survivors Feel Beautiful

NEW YORK, Jan. 2, 2024 /PRNewswire/ -- JJ's House, the renowned global online retailer specializing in wedding, occasion, prom, and party dresses, proudly announces its partnership with the Sisters in the Fight Breast Cancer Foundation, aTexas-based charity dedicated to empowering breast cancer ...

2024-01-02 21:00 1441

YolTech Therapeutics to Present and Unveil Major Progress at Biotech Showcase 2024

SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developingin vivo gene editing therapies to treat rare genetic diseases, recently announced that it will present an overview of its technology and provide corporate updates on key programs at Biotech Showcase, taking p...

2024-01-02 20:30 1495

Mabwell to attend 42nd JP Morgan Healthcare Conference and present at Biotech Showcase

SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that Dr.Hai Wu, President of R&D of Mabwell, will attend 42nd JP Morgan Healthcare Conference and present at Biotech Showcase in San Francisco, United State...

2024-01-02 17:15 1756

Ascentage Pharma to Present at 42nd J.P. Morgan Healthcare Conference

SUZHOU, China and ROCKVILLE, Md., Jan. 1, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it will attend the 42nd J.P. Morgan Healthcare ...

2024-01-02 11:58 1915

TiumBio Secures KRW 38.5 Billion in Anticipation of Upcoming Clinical Data

* The proceeds will fund its robust clinical programs and bolster TiumBio's financial position. * Data read-outs from a Phase 2 trial of merigolix in endometriosis and a Phase1b trial of TU2218 in solid tumors are expected in the first half of 2024 BOSTON and SEONGNAM, South Korea, Dec. 29, 2...

2023-12-29 21:00 2474

Meihua International Medical Technologies Co., Ltd. Announces Initial $6 Million Tranche of Potential $50.5 Million Maximum Offering

YANGZHOU, China, Dec. 28, 2023 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries inChina, announced today that it has ent...

2023-12-28 22:00 5684

Heranova Lifesciences Debuts with $13.5 Million Seed and Seed+ Round Funding to Offer Integrated Clinical Solutions to Women's Health

BOSTON and HONG KONG, Dec. 28, 2023 /PRNewswire/ -- Heranova Lifesciences Holding Ltd. ("Heranova") today announced the successful completion of aUSD 13.5 million seed and seed+ financing to develop and offer integrated Women's Health solutions worldwide. This funding will be used to launch a ...

2023-12-28 21:00 1728

Caliway to Present CBL-514 Phase 2 Study Results for Subcutaneous Fat Reduction at IMCAS 2024

CBL-514 Phase 2 Study Results for local fat reduction demonstrated 85.7% and 76.2% of participants lost at least 150mL and 200mL of abdominal subcutaneous fat in the treated area after receiving CBL-514 treatment(s). NEW TAIPEI CITY, Dec. 26, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals (Cal...

2023-12-27 11:49 1767

PharmaBlock Opens HPAPI GMP Facility at Zhejiang Manufacturing Site

NANJING, China, Dec. 26, 2023 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725.SZSE), a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has announced opening of a new high potency API (HPAPI) GMP facility (OEB-5 and ab...

2023-12-27 11:37 2047

Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs

SHANGHAI, Dec. 26, 2023 /PRNewswire/ -- Jemincare, a leading pharmaceutical company fromChina, announced that its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., recently received 6 approvals of clinical trials for its innovative drugs in the field of cancer, kidney ...

2023-12-26 17:26 1960

PharmaBlock Obtained ISO 50001 Certification, Advancing Sustainable Development

NANJING, China, Dec. 25, 2023 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725. SZSE), a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has announced the successful attainment of Energy Management System Certification...

2023-12-26 11:00 2047

Harbin City Pushes for Breakthroughs in Full Revitalization of Northeast China

HARBIN, China, Dec. 25, 2023 /PRNewswire/ -- Harbin, capital of Heilongjiang Province, has strived to build itself into a city of innovation, by sticking to reform and innovation and stimulating endogenous strength to push for breakthroughs in the full revitalization of northeastChina. The Harbi...

2023-12-25 20:42 2172

FDA Keynote Speaker in the Spotlight, CAR-T Industry Leaders Gather for Discussion-Join the 2024 GenScript Biotech Global Forum for a New Journey in Cell and Gene Therapy

NANJING, China, Dec. 24, 2023 /PRNewswire/ -- The innovative development of biopharmaceuticals has ushered in a new era for disease treatment, bringing unprecedented hope to countless patients. However, the transition from basic research to clinical commercialization presents formidable challenge...

2023-12-25 10:15 2124
1 ... 53545556575859 ... 279